Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Mar 04, 2023 5:00pm
96 Views
Post# 35319503

RE:RE:Majority of population overweight/obese by 2035

RE:RE:Majority of population overweight/obese by 2035

They have to file the sBLA for F8 by March 2024(patent expiration 2033/34) so it will be replacing Egrifta SV for lipo patients. 

As for NAFLD/NASH they also have patents expiration 2040. 

As for ROI I agree it has been a disaster so far.

"In the United States, we own three patents relating to the use of tesamorelin in the treatment of HIV-associated lipodystrophy, which are scheduled to expire in August 2023;

We also own patents in several other countries relating to the use of tesamorelin in the treatment of HIV--associated lipodystrophy, which are scheduled to expire from May 2023 to October 2025;

In the United States, we have the exclusive rights to two patents that claim methods for the treatment of NAFL or NASH in a patient, as well as for reducing liver fibrosis and the risk of liver cancer in such patients, via the administration of tesamorelin. These patents are scheduled to expire in 2040;

In the United States, we also have the exclusive rights to an additional patent application that claims a method for preventing or delaying the onset of cirrhosis or for treating cirrhosis, in a patient suffering from NAFL or NASH, via the administration of tesamorelin. This application, if granted, would be scheduled to expire in 2040;

We also have the exclusive rights to patent applications in several other countries relating to the treatment of NAFL or NASH in a patient. These applications, if granted, would be scheduled to expire in 2040;

In the United States and in certain major European countries, we own patents relating to the F8 Formulation, which are scheduled to expire in 2033 and 2034, respectively;

We have also filed patent applications in the US and Canada related to the use of the F4 formulation in a treatment regimen bioequivalent to the original formulation of EGRIFTA®. These applications, if granted, would be scheduled to expire in 2039; and

We have also filed a PCT patent application in June 2021 and are currently filing corresponding patent applications in the US and several other jurisdictions, relating to the use of the F8 formulation in a treatment regimen bioequivalent to the original formulation of EGRIFTA®. These applications, if granted, would be scheduled to expire in 2041."

https://www.biospace.com/article/releases/theratechnologies-confirms-bioequivalence-of-new-tesamorelin-formulation/

<< Previous
Bullboard Posts
Next >>